Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Jump Financial LLC

Jump Financial LLC cut its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 68.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,601 shares of the company's stock after selling 31,006 shares during the quarter. Jump Financial LLC's holdings in Kiniksa Pharmaceuticals were worth $289,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter worth about $158,000. China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after purchasing an additional 719 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $258,000. Finally, New York State Common Retirement Fund increased its stake in Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock valued at $302,000 after purchasing an additional 1,680 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Trading Down 0.8 %

Shares of Kiniksa Pharmaceuticals stock traded down $0.23 on Friday, reaching $27.51. 196,247 shares of the stock were exchanged, compared to its average volume of 476,307. The firm has a market capitalization of $2.00 billion, a PE ratio of -196.52 and a beta of 0.31. The business has a fifty day moving average price of $21.61 and a two-hundred day moving average price of $21.35. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $17.38 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the previous year, the company earned ($0.25) EPS. The company's quarterly revenue was up 72.5% on a year-over-year basis. Research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 21,254 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total value of $572,795.30. Following the completion of the transaction, the chief financial officer now directly owns 27,009 shares in the company, valued at $727,892.55. This trade represents a 44.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 218,548 shares of company stock valued at $5,210,745. Company insiders own 54.57% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on KNSA shares. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday. Wedbush reissued an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of "Buy" and a consensus target price of $38.00.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.